Figures & data
Figure 1. Patient disposition. aSafety analysis set defined as all patients who received ≥1 dose of study drug during the study observation period. bMost common reasons for discontinuation (≥2% in any group). cFull analysis set defined as all patients who received ≥1 dose of study drug during the study observation period and had ≥1 post-dose assessment of any of the effectiveness endpoints.
![Figure 1. Patient disposition. aSafety analysis set defined as all patients who received ≥1 dose of study drug during the study observation period. bMost common reasons for discontinuation (≥2% in any group). cFull analysis set defined as all patients who received ≥1 dose of study drug during the study observation period and had ≥1 post-dose assessment of any of the effectiveness endpoints.](/cms/asset/00623301-a9e1-4536-b2e4-d6674d4412f2/iebt_a_2200883_f0001_oc.jpg)
Table 1. Population characteristics and drug utilization patterns (safety analysis set).
Table 2. Summary of TEAEs (safety analysis set).
Table 3. Summary of all-causality TEAEs (SOC and PT ≥ 2% of patients in either cohort) (safety analysis set).a
Figure 2. Rates of clinical remissiona over time following treatment with CT-P13 and IFX-RP for patients with IBD overall, (a) and (b), respectively, and by disease type (CD and UC), (c) and (d) respectively (full analysis set). aBased on physician assessment.
![Figure 2. Rates of clinical remissiona over time following treatment with CT-P13 and IFX-RP for patients with IBD overall, (a) and (b), respectively, and by disease type (CD and UC), (c) and (d) respectively (full analysis set). aBased on physician assessment.](/cms/asset/49ceb43a-2215-4182-ae48-83969610a8c4/iebt_a_2200883_f0002_b.gif)
Figure 3. Change in disease status over time for patients with IBD overall (CD and UC) treated with (a) CTP13 and (b) IFX-RP (full analysis set). aChange from baseline to analysis timepoint = (mild disease to mild disease) + (mild disease to moderate disease) + (mild disease to severe disease) + (moderate disease to moderate disease) + (moderate disease to severe disease) + (severe disease to severe disease). bChange from baseline to analysis timepoint = (clinical remission to mild disease) + (clinical remission to moderate disease) + (clinical remission to severe disease).
![Figure 3. Change in disease status over time for patients with IBD overall (CD and UC) treated with (a) CTP13 and (b) IFX-RP (full analysis set). aChange from baseline to analysis timepoint = (mild disease to mild disease) + (mild disease to moderate disease) + (mild disease to severe disease) + (moderate disease to moderate disease) + (moderate disease to severe disease) + (severe disease to severe disease). bChange from baseline to analysis timepoint = (clinical remission to mild disease) + (clinical remission to moderate disease) + (clinical remission to severe disease).](/cms/asset/5386668a-4d6b-4d4f-ab1e-58d41ba0392a/iebt_a_2200883_f0003_b.gif)